274 related articles for article (PubMed ID: 35565229)
1. Modulation of the Gut Microbiome to Improve Clinical Outcomes in Hepatocellular Carcinoma.
Shen S; Khatiwada S; Behary J; Kim R; Zekry A
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565229
[TBL] [Abstract][Full Text] [Related]
2. Unveiling the complex relationship between gut microbiota and liver cancer: opportunities for novel therapeutic interventions.
Rajapakse J; Khatiwada S; Akon AC; Yu KL; Shen S; Zekry A
Gut Microbes; 2023 Dec; 15(2):2240031. PubMed ID: 37615334
[TBL] [Abstract][Full Text] [Related]
3. Potential tactics with certain gut microbiota for the treatment of unresectable hepatocellular carcinoma.
Yoshikawa S; Taniguchi K; Sawamura H; Ikeda Y; Asai T; Tsuji A; Matsuda S
Explor Target Antitumor Ther; 2023; 4(4):556-568. PubMed ID: 37720344
[TBL] [Abstract][Full Text] [Related]
4. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome.
Golonka RM; Vijay-Kumar M
Adv Cancer Res; 2021; 149():171-255. PubMed ID: 33579424
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiota modulate radiotherapy-associated antitumor immune responses against hepatocellular carcinoma Via STING signaling.
Li Z; Zhang Y; Hong W; Wang B; Chen Y; Yang P; Zhou J; Fan J; Zeng Z; Du S
Gut Microbes; 2022; 14(1):2119055. PubMed ID: 36093568
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome.
Temraz S; Nassar F; Kreidieh F; Mukherji D; Shamseddine A; Nasr R
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360566
[TBL] [Abstract][Full Text] [Related]
7. The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma.
Gok Yavuz B; Datar S; Chamseddine S; Mohamed YI; LaPelusa M; Lee SS; Hu ZI; Koay EJ; Tran Cao HS; Jalal PK; Daniel-MacDougall C; Hassan M; Duda DG; Amin HM; Kaseb AO
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835569
[TBL] [Abstract][Full Text] [Related]
8. The Gut Microbiome and Hepatocellular Carcinoma: Implications for Early Diagnostic Biomarkers and Novel Therapies.
Kang Y; Cai Y; Yang Y
Liver Cancer; 2022 Apr; 11(2):113-125. PubMed ID: 35634424
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome.
Vaziri F; Colquhoun S; Wan YY
Liver Res; 2020 Dec; 4(4):191-198. PubMed ID: 33343967
[TBL] [Abstract][Full Text] [Related]
10. Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy.
Wan MLY; El-Nezami H
Hepatobiliary Surg Nutr; 2018 Feb; 7(1):11-20. PubMed ID: 29531939
[TBL] [Abstract][Full Text] [Related]
11. Gut Microbiota and Hepatocellular Carcinoma.
Tao X; Wang N; Qin W
Gastrointest Tumors; 2015 May; 2(1):33-40. PubMed ID: 26673641
[TBL] [Abstract][Full Text] [Related]
12. Defining the temporal evolution of gut dysbiosis and inflammatory responses leading to hepatocellular carcinoma in Mdr2 -/- mouse model.
Behary J; Raposo AE; Amorim NML; Zheng H; Gong L; McGovern E; Chen J; Liu K; Beretov J; Theocharous C; Jackson MT; Seet-Lee J; McCaughan GW; El-Omar EM; Zekry A
BMC Microbiol; 2021 Apr; 21(1):113. PubMed ID: 33858327
[TBL] [Abstract][Full Text] [Related]
13. Gut microbiome in HCC - Mechanisms, diagnosis and therapy.
Schwabe RF; Greten TF
J Hepatol; 2020 Feb; 72(2):230-238. PubMed ID: 31954488
[TBL] [Abstract][Full Text] [Related]
14. Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma.
Huang H; Ren Z; Gao X; Hu X; Zhou Y; Jiang J; Lu H; Yin S; Ji J; Zhou L; Zheng S
Genome Med; 2020 Nov; 12(1):102. PubMed ID: 33225985
[TBL] [Abstract][Full Text] [Related]
15. Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma: Current knowledge and potential for therapeutics.
Said I; Ahad H; Said A
World J Gastrointest Oncol; 2022 May; 14(5):947-958. PubMed ID: 35646285
[TBL] [Abstract][Full Text] [Related]
16. The Potential Gut Microbiota-Mediated Treatment Options for Liver Cancer.
Zhang C; Yang M; Ericsson AC
Front Oncol; 2020; 10():524205. PubMed ID: 33163393
[TBL] [Abstract][Full Text] [Related]
17. The Microbiome and Liver Cancer.
Myojin Y; Greten TF
Cancer J; 2023 Mar-Apr 01; 29(2):57-60. PubMed ID: 36957974
[TBL] [Abstract][Full Text] [Related]
18. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
19. Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis.
Jiang JW; Chen XH; Ren Z; Zheng SS
Hepatobiliary Pancreat Dis Int; 2019 Feb; 18(1):19-27. PubMed ID: 30527903
[TBL] [Abstract][Full Text] [Related]
20. The gut microbiome and liver cancer: mechanisms and clinical translation.
Yu LX; Schwabe RF
Nat Rev Gastroenterol Hepatol; 2017 Sep; 14(9):527-539. PubMed ID: 28676707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
